• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Taysha Gene Therapies Inc.

    1/7/25 4:34:13 PM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TSHA alert in real time by email
    S-8 1 d879414ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on January 7, 2025

    Registration No. 333-   

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    Taysha Gene Therapies, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   84-3199512

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    3000 Pegasus Park Drive

    Suite 1430

    Dallas, Texas 75247

    (Address of principal executive offices, including zip code)

    Taysha Gene Therapies, Inc. 2020 Stock Incentive Plan

    Taysha Gene Therapies, Inc. 2020 Employee Stock Purchase Plan

    Taysha Gene Therapies, Inc. 2023 Inducement Plan

    (Full titles of the plans)

    Sean P. Nolan

    Chief Executive Officer

    3000 Pegasus Park Drive

    Suite 1430

    Dallas, Texas 75247

    (214) 612-0000

    (Name, address and telephone number, including area code, of agent for service)

     

     

    Copies to:

    Divakar Gupta

    Madison A. Jones

    Cooley LLP

    55 Hudson Yards

    New York, New York 10001

    Telephone: (212) 479-6000

    Facsimile: (212) 479-6275

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


    EXPLANATORY NOTE

    REGISTRATION OF ADDITIONAL SHARES

    Pursuant to General Instruction E of Form S-8, Taysha Gene Therapies, Inc. (the “Registrant”) is filing this Registration Statement on Form S-8 with the Securities and Exchange Commission (the “Commission”) for the purpose of registering (i) 10,247,165 additional shares of its common stock under the Registrant’s 2020 Stock Incentive Plan (the “2020 Plan”), pursuant to the provisions of the 2020 Plan providing for an automatic increase in the number of shares of common stock reserved and available for issuance under the 2020 Plan on January 1, 2025, (ii) 724,000 additional shares of its common stock under the Registrant’s 2020 Employee Stock Purchase Plan (the “2020 ESPP”), pursuant to the provisions of the 2020 ESPP providing for an automatic increase in the number of shares of common stock reserved and available for issuance under the 2020 ESPP on January 1, 2025 and (iii) 2,000,000 shares of its common stock under the Registrant’s 2023 Inducement Plan (the “Inducement Plan”). The additional shares of common stock under the Inducement Plan represent an increase in the number of shares of common stock reserved for issuance under the Inducement Plan, which increase was approved by the Compensation Committee of the Registrant’s Board of Directors on December 12, 2024. In accordance with the instructional note to Part I of Form S-8 as promulgated by the Commission, the information specified by Part I of the Form S-8 has been omitted from this Registration Statement.

    The Registrant previously registered shares of its common stock for issuance under the 2020 Plan and the 2020 ESPP on a Registration Statement on Form S-8 filed with the Commission on September 29, 2020 (File No.  333-249130), a Registration Statement on Form S-8 filed with the Commission on May 11, 2021 (File No. 333-256013), a Registration Statement on Form S-8 filed with the Commission on March 31, 2022 (File No. 333-264025), a Registration Statement on Form S-8 filed with the Commission on March 28, 2023 (File No. 333-270915) and a Registration Statement on Form S-8 filed with the Commission on March 19, 2024 (File No. 333-278070), and under its Inducement Plan on a Registration Statement on Form S-8 filed with the Commission on December 20, 2023 (File No.  333-276161). Pursuant to General Instruction E to Form S-8, this Registration Statement hereby incorporates by reference the contents of the Registration Statements referenced above except to the extent supplemented, amended or superseded by the information set forth herein.

    PART II

    INFORMATION REQUIRED IN REGISTRATION STATEMENT

    ITEM 3. INCORPORATION OF DOCUMENTS BY REFERENCE

    The following documents filed by the Registrant with the Commission are incorporated by reference into this Registration Statement:

     

      (a)

    The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Commission on March 19, 2024.

     

      (b)

    The information specifically incorporated by reference into the Registrant’s Annual Report on Form 10-K for the year ended December  31, 2023 from the Registrant’s Definitive Proxy Statement on Schedule 14A filed with the Commission on April 18, 2024.

     

      (c)

    the Registrant’s Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2024, June 30, 2024 and September 30, 2024, filed with the SEC on May 14, 2024, August 12, 2024 and November 13, 2024, respectively.

     

      (d)

    The Registrant’s Current Reports on Form 8-K filed with the Commission on May  30, 2024, June  26, 2024 and June 26, 2024, to the extent the information in such report is filed and not furnished.


      (e)

    The description of the Registrant’s common stock which is contained in Exhibit 4.1 in the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, filed on August 12, 2024, including any amendment or report filed with the Commission for the purpose of updating such description.

     

      (f)

    All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14, and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.


    ITEM 8. EXHIBITS

     

              Incorporated by Reference  

    Exhibit

    Number

      

    Description

       Schedule
    Form
         File Number      Exhibit      Filing Date  
     4.1    Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect      8-K        001-39536        3.1        September 29, 2020  
     4.2    Certificate of Amendment to the Amended and Restated Certificate of Incorporation      8-K        001-39536        3.1        November 15, 2023  
     4.3    Amended and Restated Bylaws of the Registrant, as currently in effect      S-1/A        333-248559        3.4        September 17, 2020  
     5.1*    Opinion of Cooley LLP.            
    23.1*    Consent of Cooley LLP (included in Exhibit 5.1).            
    23.2*    Consent of Deloitte & Touche LLP, independent registered public accounting firm.            
    24.1*    Power of Attorney (included on the signature page of this Form S-8).            
    99.1    2020 Stock Incentive Plan and Forms of Stock Option Grant Notice, Stock Option Agreement, Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement      S-1/A        333-248559        10.6        September 17, 2020  
    99.2    2020 Employee Stock Purchase Plan      S-1/A        333-248559        10.7        September 17, 2020  
    99.3    Taysha Gene Therapies, Inc. 2023 Inducement Plan.      S-8        333-276161        99.1        December 20, 2023  
    99.4    Form of Option Grant Package under 2023 Inducement Plan.      S-8        333-276161        99.2        December 20, 2023  
    99.5    Form of RSU Grant Package under 2023 Inducement Plan.      S-8        333-276161        99.3        December 20, 2023  
    99.6*    Amendment to 2023 Inducement Plan            
    107*    Filing Fee Table            

     

    *

    Filed herewith.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Dallas, State of Texas, on this 7th day of January, 2025.

     

    TAYSHA GENE THERAPIES, INC.
    By:   /s/ Sean P. Nolan
      Sean P. Nolan
      Chief Executive Officer

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Sean P. Nolan and Kamran Alam, and each one of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in their name, place or stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Name

      

    Title

     

    Date

    /s/ Sean P. Nolan

    Sean P. Nolan

      

    Chief Executive Officer and Chairman

    (Principal Executive Officer)

      January 7, 2025

    /s/ Kamran Alam

    Kamran Alam

       Chief Financial Officer (Principal Financial and Accounting Officer)   January 7, 2025

    /s/ Phillip B. Donenberg

    Phillip B. Donenberg

       Director   January 7, 2025

    /s/ Sean Stalfort

    Sean Stalfort

       Director   January 7, 2025

    /s/ Sukumar Nagendran, M.D.

    Sukumar Nagendran, M.D.

      

    President, Head of Research and

    Development, and Director

      January 7, 2025

    /s/ Alison Long, M.D., Ph.D.

    Alison Long, M.D., Ph.D.

       Director   January 7, 2025

    /s/ Laura Sepp-Lorenzino, Ph.D.

    Laura Sepp-Lorenzino, Ph.D.

       Director   January 7, 2025
    Get the next $TSHA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TSHA

    DatePrice TargetRatingAnalyst
    6/27/2024$5.00Outperform
    BMO Capital Markets
    4/9/2024$9.00Overweight
    Piper Sandler
    2/1/2023$14.00 → $1.50Buy → Hold
    Jefferies
    1/27/2023$23.00 → $3.00Overweight → Equal-Weight
    Morgan Stanley
    11/9/2022$16.00 → $3.00Buy → Neutral
    Goldman
    3/9/2022$26.00Outperform
    Robert W. Baird
    3/9/2022$26.00Outperform
    Baird
    3/1/2022$25.00Overweight
    Wells Fargo
    More analyst ratings